Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Claude Cormier who wrote (8420)	1/14/2002 12:36:12 AM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

bonjour Claude, <Failure to get at least the first 4 is fatal and the end of my investment in DMX > And what is the probabilité on this? With the Euro market getting 2 of the big 4 and few of the smaller countries, unless things change it is unlikely to sustain Dimethaid without more big markets. While Canada adds another reasonable market, DMX must enter the US with Pennsaid to catch the wave. Entrance into the US is virtually guaranteed success for current DMX shareholders. Failure to achieve that pushes all hopes onto WF10 which alone has huge potential; but, unlikely enough to offset shareholder reaction to the loss of this market. I personally believe the odds of not passing inspection after at least one more round are near zero and that successful inspection truly will trigger the J&J deal. They will jointly present the marketing plan to the FDA and I believe J&J must be involved in the final labelling decisions. I put market launch as slightly better than 50/50 this year - but believe it is only a matter of time. Are Asia and Australia target markets at all ? I believe they are; but, not in my mind in a sufficient timeframe to affect 2002 shareprice. Wolf